MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • MassDevice Today
    • Cardiovascular
    • Clinical Trials
    • Legal News
    • Orthopedics
    • Regulatory/Compliance
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • More MedTech
    • Cosmetic/Aesthetic
    • Diabetes
    • Dialysis
    • Distribution
    • Imaging
    • Otolaryngology Ear, Nose & Throat
    • Pharma
    • Respiratory
    • Wound Care
  • Blog
  • DeviceTalks Podcasts
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • Videos
    • White Papers
  • DeviceTalks
Home » Number of cancer cases linked to breast implants soars

Number of cancer cases linked to breast implants soars

February 7, 2019 By Nancy Crotti Leave a Comment

Share

FDA-logo-newFDA said it has received reports of 457 unique cancer cases related to breast implants since 2010, including nine patient deaths.

The agency identified those unique cases from a total of 660 adverse event reports in the U.S. from 2010 through September 2018, including 246 new adverse event reports since 2017.

FDA began reporting on cases of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a type of non-Hodgkin’s lymphoma and a known risk from breast implants, in 2011. The new total of reports is larger than the number of unique cases because patients, providers, and manufacturers may all report an incident, resulting in duplicative reports.

The increase in reports may also be due to heightened FDA efforts to communicate BIA-ALCL risks, an increased understanding of this particular type of cancer, and a more thorough analysis of adverse event reports, according to the agency.

“It is crucial to understand that due to under-reporting and missing data, the FDA is unable to confirm whether this dataset reflects the distribution of all BIA-ALCL cases,” FDA said in a prepared statement.

“We want to provide patients with the most up-to-date information about the variety of breast implants available so that patients and providers can have thorough and thoughtful discussions weighing the benefits and risks of different products,” added Binita Ashar, M.D., of FDA’s Center for Devices and Radiological Health (CDRH), in a separate statement. “We also want to be transparent in sharing the information we regularly gather and analyze in a way that provides important context to help inform these discussions…

“We hope that this information prompts providers and patients to have important, informed conversations about breast implants and the risk of BIA-ALCL,” continued Ashar, who is director of CDRH’sDivision of Surgical Devices. “At the same time, we remain committed to working in partnership with all stakeholders to continue to study, understand and provide updates about this important public health issue.”

Ashar also acknowledged the regulatory actions of FDA counterparts in different countries in response to reports of BIA-ALCL cases. Allergan (NYSE: AGN) removed its textured breast implants from the market in Europe in December, following a request from French regulators. The New York Times reported that the implants were linked to an uncommon form of lymphoma that can arise years after the implant is placed.

“The different devices approved in each country, availability of products, variation in market share, extent of medical device adverse event reporting, and availability of information regarding the total number of implants sold differs from country to country,” Ashar said. “This makes it difficult for the regulatory bodies of different countries to compare data and determine risk rates on a global scale…

“We recognize the limitations of medical device reports, which is why we review other sources of information, including medical literature and the Patient Registry and Outcomes for Breast Implants and Anaplastic Large Cell Lymphoma Etiology and Epidemiology (PROFILE).”

PROFILE collects real-world data regarding patients who have a confirmed diagnosis of BIA-ALCL.

FDA also said it is issuing a letter to healthcare providers to encourage those who regularly treat patients, including primary care physicians and gynecologists, to learn about BIA-ALCL in patients with breast implants. BIA-ALCL will be discussed at a public meeting of the FDA’s General and Plastic Surgery Devices Panel at its headquarters in Silver Spring, Md. on March 25-26.

Filed Under: Blog, Featured, Food & Drug Administration (FDA), Implants, News Well, Oncology, Women's Health Tagged With: Allergan, Center for Devices and Radiological Health (CDRH), FDA

In case you missed it

  • Here’s how a new Abbott device is making a difference among neonatal infants
  • Conformis: Yale study shows customized knee implants save money
  • Intuitive Surgical wins FDA clearance for robotic-assisted lung biopsy system
  • Medtronic risk prediction tool could help prevent opioid deaths: Here’s how
  • Phillips-Medisize is expanding in Wisconsin
  • NuVasive wins FDA, CE Mark for Precice internal bone transport system
  • Cash-strapped Aradigm declares bankruptcy
  • ReWalk Robotics files for exoskeleton suit clearance
  • Hancock Jaffe launches first-in-human VenoValve study
  • Medtronic shares rise on FY2019 Q3 earnings beat
  • Medtronic: Patient deaths left out of paclitaxel-coated balloon analysis
  • Teva aims for 25% of U.S. EpiPen market by 2020
  • Medtronic wins FDA’s breakthrough status for closed-loop insulin system
  • India CDSCO adds new medical devices to regulated list
  • Judge sends ‘brain fingerprinting company’ and would-be distributor to arbitration
  • FDA gives massive Medtronic recall Class I designation
  • Affluent Medical touts results of endovascular aneurysm repair study

RSS From Medical Design & Outsourcing

  • Medtronic risk prediction tool could help prevent opioid deaths: Here’s how
    Medtronic officials continue to hone their arguments for how the company’s capnography and oximetry systems could reduce potentially deadly opioid-induced respiratory compromise. The medical device giant on Feb. 17 announced preliminary results of its Prodigy study, in which the company’s Microstream and Nellcor monitoring technology provided continuous capnography and oximetry for 1,496 patients across 16 sites in the U.S.,… […]
  • Phillips-Medisize is expanding in Wisconsin
    Phillips-Medisize, a Molex company, has broken ground on a new manufacturing facility in Hudson, Wis., on the eastern end of the Minneapolis-St. Paul metro area. The 34-acre location at the St. Croix Meadows development will support at least 230,000 square feet of manufacturing space for FDA-regulated medical device products, Phillips-Medisize announced yesterday. After construction is complete… […]
  • ReWalk Robotics files for exoskeleton suit clearance
      ReWalk Robotics (NSDQ:RWLK) said it has applied to FDA for 510(k) clearance of its ReStore exoskeleton suit for gait training during stroke rehabilitation. The Yokneam, Israel-based company designed its exo-suit to provide coordinated plantarflexion and dorsiflexion assistance to a patient’s foot and ankle. It recently won insurer reimbursement from Cigna and completed a clinical… […]
  • FDA proposes faster post-inspection feedback
    FDA has issued draft guidance providing for more timely nonbinding feedback following medtech facility inspections to advise whether the companies’ proposed corrective actions appear adequate to the agency. The draft guidance proposes a process by which companies can request nonbinding feedback on certain kinds of observations issued on a Form 483. It outlines a standardized method… […]
  • India CDSCO adds new medical devices to regulated list
    By Stewart Eisenhart, Emergo Group India’s Central Drugs Standard Control Organization (CDSCO) continues expanding oversight to more types of medical devices, now planning to require registration for eight additional device types starting April 1, 2020. Get the full story here at the Emergo Group’s blog. The opinions expressed in this blog post are the author’s… […]
  • Empowering Medical Innovation
    From faster medical device development to life-saving surgical planning models, see how full-color, multi-material 3D printing opens up broad possibilities for medical innovation. In this new E-book you’ll learn how the Stratasys J750 can: Produce superior medical models for surgical planning and training Foster better medical devices through faster ideation and prototyping Enable advanced training… […]
  • Affluent Medical touts results of endovascular aneurysm repair study
    Medtech startup Affluent Medical(Paris, France) said a study of its endovascular aneurysm repair (EVAR) system device showed patients had fewer endoleaks and needed fewer secondary interventions, and that their aneurysms shrank in volume and diameter. The company’s Kardiozis endovascular prosthesis uses thrombogenic fibers to embolize an abdominal aortic aneurism sac during a conventional EVAR procedure to prevent… […]
  • This cotton-based biofuel cell could power implanted medical devices
    Researchers at the Georgia Institute of Technology and Korea University have developed a glucose-powered biofuel cell that uses electrodes from cotton that could potentially power implantable medical devices. The fuel cell has twice as much power as traditional biofuel cells and could also be paired with batteries or super capacitors to create a hybrid power… […]
  • IEEE publishes safety standards draft for medtech interoperability
    The Institute of Electrical and Electronics Engineers (IEEE) Standards Association said it has published a draft set of standards intended to provide safe and secure medical device interoperability. IEEE 11073-20701-2018, also known as IEEE Approved Draft Standard for Service-Oriented Medical Device Exchange Architecture & Protocol Binding, completes the International Organization for Standardization (ISO)/IEEE 11073 family of standards… […]
  • FDA clears Safe Medical Design’s urethral catheter
    Safe Medical Design (San Francisco) said that FDA has cleared its Signal Catheter for commercialization in the United States. The 100% silicone foley catheter features a novel hub design allowing the catheter to reduce excessive balloon pressure in the event the catheter is improperly placed. Each year in the United States there are as many as 500,000… […]
  • These medtech companies raised the most VC in 2018
    Venture capital firms invested more than $2.9 billion in medical device companies in 2018 — a slight increase from the $2.8 billion raised in 2017, according to the MoneyTree report from PricewaterhouseCoopers (PwC) and CB Insights. Both the first and second quarters of 2018 saw an increase in investments, totaling nearly $778 million and $786 million respectively.… […]

Leave a Reply Cancel reply

You must be logged in to post a comment.

Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us
Privacy
Add us on FacebookMassDevice Network
Follow us on Twitter@MassDevice
Connect with us on LinkedInLinkedIn
Follow us on YouTube YouTube

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS